TY - CHAP
T1 - Modeling human prostate cancer in genetically engineered mice
AU - Wang, Fen
N1 - Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2011
Y1 - 2011
N2 - The progression of prostate cancer is a slow and multiple-step process; clinically detectable prostate cancer normally manifest in aged men, although the lesions may have originated much earlier in life. Animal models that mimic the initiation, progression, and metastasis of human prostate cancer are needed to understand the etiology of prostate cancer and to develop new treatments. Recent progress in mouse genetic engineering technology has led to generation of a series of mouse models for prostate cancer research, which have been widely used for testing impacts of a single or combinations of several gene alterations on the onset, progression, and metastasis of prostate tumors, as well as for assessing the effects of environmental, clinical, and preclinical drugs for prostate cancer prevention and treatment. Although it is possible that no single "perfect" model can recapitulate every aspects of this highly heterogeneous disease, it is expected that the models mimicking certain aspects of prostate cancers will continue to provide preclinical guide to treat this prevalent disease.
AB - The progression of prostate cancer is a slow and multiple-step process; clinically detectable prostate cancer normally manifest in aged men, although the lesions may have originated much earlier in life. Animal models that mimic the initiation, progression, and metastasis of human prostate cancer are needed to understand the etiology of prostate cancer and to develop new treatments. Recent progress in mouse genetic engineering technology has led to generation of a series of mouse models for prostate cancer research, which have been widely used for testing impacts of a single or combinations of several gene alterations on the onset, progression, and metastasis of prostate tumors, as well as for assessing the effects of environmental, clinical, and preclinical drugs for prostate cancer prevention and treatment. Although it is possible that no single "perfect" model can recapitulate every aspects of this highly heterogeneous disease, it is expected that the models mimicking certain aspects of prostate cancers will continue to provide preclinical guide to treat this prevalent disease.
UR - http://www.scopus.com/inward/record.url?scp=79952383626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952383626&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-384878-9.00001-7
DO - 10.1016/B978-0-12-384878-9.00001-7
M3 - Chapter
C2 - 21377623
AN - SCOPUS:79952383626
T3 - Progress in Molecular Biology and Translational Science
SP - 1
EP - 49
BT - Progress in Molecular Biology and Translational Science
PB - Elsevier B.V.
ER -